A telehealth brand offers compounded GLP-1 therapy, hormone replacement therapy, and NAD+ on a monthly subscription basis, targeting primarily perimenopausal women, with a men's metabolic segment as a secondary focus. The business has cemented its market positioning through strategic regulatory assets that include LegitScript Healthcare Certification valid until May 2027. This opens access to prescription-drug advertising on major platforms, such as Google and Meta, giving it a competitive edge over uncertified competitors. The business operates as an orchestrated layer without direct clinical or fulfillment staffing, relying on an outsourced telehealth infrastructure for intake, provider review, pharmacy fulfillment, and billing. The company’s customer acquisition funnel has been rigorously tested and validated, demonstrating successful conversion from initial customer engagement to paid subscription. The operation is structured as an LLC, maintaining the critical certifications and agreements essential for continued operation. Included in the sale are numerous assets like the LegitScript certification, a Google Ads account optimized for prescription advertising, and a Meta Business Portfolio, among others. Growth opportunities for a buyer include reactivating paid search campaigns, launching the hormone replacement therapy line, leveraging the Meta channel, and integrating existing wellness/health traffic for monetization purposes. The solo founder is selling the business at $49,000, valuing it on replacement cost to offer a head start into the regulated telehealth market. This price saves months of establishment time and financial investment for potential buyers. The sale is positioned as an infrastructure opportunity, ready to scale with the right owner or additional operational focus.